Alto Neuroscience (ANRO) Enterprise Value (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Enterprise Value data on file, last reported at -$263.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 64.08% year-over-year to -$263.8 million; the trailing twelve-month figure through Mar 2026 stood at -$263.8 million (down 64.08% YoY), and the FY2025 full-year result was -$176.5 million, down 4.93% from the prior year.
• Enterprise Value declined to -$263.8 million in Q1 2026, from -$176.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$82.5 million in Q4 2023 to a low of -$263.8 million in Q1 2026.
• A 4-year average of -$171.8 million and a median of -$172.3 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value plunged 103.76% in 2024 and climbed 24.15% in 2025, its largest moves.
• Tracing ANRO's Enterprise Value over 4 years: stood at -$82.5 million in 2023, then plunged by 103.76% to -$168.2 million in 2024, then slipped by 4.93% to -$176.5 million in 2025, then sank by 49.45% to -$263.8 million in 2026.
• Business Quant data shows ANRO's Enterprise Value at -$263.8 million in Q1 2026, -$176.5 million in Q4 2025, and -$137.8 million in Q3 2025.